NovoCure Limited (NVCR)
NASDAQ$19.49
Market Cap
$2.14B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
746 of 924
Rank in Industry
40 of 47
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
NVCR Insider Trading Activity
NVCR Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $997,684 | 22 | 100 |
Related Transactions
| Leupin Nicolas | Chief Medical Officer | 0 | $0 | 1 | $19,844 | $-19,844 |
| LEUNG GABRIEL | director | 0 | $0 | 1 | $23,025 | $-23,025 |
| Scannell Timothy J | director | 0 | $0 | 1 | $23,027 | $-23,027 |
| VERNON W ANTHONY | director | 0 | $0 | 1 | $23,033 | $-23,033 |
| Puri Michal Nath | Chief Human Resources Officer | 0 | $0 | 2 | $40,564 | $-40,564 |
| Weinberg Uri | Chief Innovation Officer | 0 | $0 | 2 | $92,020 | $-92,020 |
| Paravasthu Mukund | Chief Operating Officer | 0 | $0 | 6 | $105,502 | $-105,502 |
| Cordova Ashley | Chief Financial Officer | 0 | $0 | 4 | $318,039 | $-318,039 |
| Leonard Frank X | EVP, Pres., Novocure Oncology | 0 | $0 | 4 | $352,629 | $-352,629 |
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver …
Insider Activity of NovoCure Limited
Over the last 12 months, insiders at NovoCure Limited have bought $0 and sold $997,684 worth of NovoCure Limited stock.
On average, over the past 5 years, insiders at NovoCure Limited have bought $433,297 and sold $39.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,974 shares for transaction amount of $509,539 was made by Danziger Asaf (Chief Executive Officer) on 2021‑11‑26.
List of Insider Buy and Sell Transactions, NovoCure Limited
| 2025-03-03 | Sale | Cordova Ashley | Chief Executive Officer | 2,053 0.0019% | $18.54 | $38,055 | +8.96% | |
| 2025-03-03 | Sale | Weinberg Uri | Chief Innovation Officer | 268 0.0003% | $18.92 | $5,071 | +8.96% | |
| 2025-03-03 | Sale | Leonard Frank X | EVP, Pres., Novocure Oncology | 2,527 0.0024% | $18.54 | $46,841 | +8.96% | |
| 2025-03-03 | Sale | Paravasthu Mukund | Chief Operating Officer | 250 0.0002% | $18.54 | $4,634 | +8.96% | |
| 2025-02-28 | Sale | Cordova Ashley | Chief Executive Officer | 2,341 0.0021% | $18.28 | $42,804 | +3.70% | |
| 2025-02-28 | Sale | Weinberg Uri | Chief Innovation Officer | 4,637 0.0042% | $18.75 | $86,949 | +3.70% | |
| 2025-02-28 | Sale | Leonard Frank X | EVP, Pres., Novocure Oncology | 2,770 0.0025% | $18.28 | $50,648 | +3.70% | |
| 2025-02-28 | Sale | Paravasthu Mukund | Chief Operating Officer | 368 0.0003% | $18.28 | $6,729 | +3.70% | |
| 2025-02-27 | Sale | Cordova Ashley | Chief Executive Officer | 11,153 0.0106% | $20.02 | $223,323 | +1.35% | |
| 2025-02-27 | Sale | Leonard Frank X | EVP, Pres., Novocure Oncology | 12,266 0.0117% | $20.02 | $245,609 | +1.35% | |
| 2025-02-27 | Sale | Puri Michal Nath | Chief Human Resources Officer | 1,387 0.0013% | $20.02 | $27,773 | +1.35% | |
| 2025-02-27 | Sale | Leupin Nicolas | Chief Medical Officer | 991 0.0009% | $20.02 | $19,844 | +1.35% | |
| 2025-02-27 | Sale | Paravasthu Mukund | Chief Operating Officer | 1,646 0.0016% | $20.02 | $32,959 | +1.35% | |
| 2025-01-11 | Sale | Paravasthu Mukund | Chief Operating Officer | 2,160 0.002% | $26.81 | $57,906 | -2.10% | |
| 2024-11-02 | Sale | Paravasthu Mukund | Chief Operating Officer | 44 <0.0001% | $16.69 | $734 | 0.00% | |
| 2024-11-01 | Sale | Leonard Frank X | EVP, Pres., Novocure Oncology | 598 0.0005% | $15.94 | $9,531 | +41.72% | |
| 2024-11-01 | Sale | Paravasthu Mukund | Chief Operating Officer | 160 0.0001% | $15.88 | $2,540 | +41.72% | |
| 2024-10-31 | Sale | Puri Michal Nath | Chief Human Resources Officer | 810 0.0008% | $15.79 | $12,792 | +49.57% | |
| 2024-08-02 | Sale | Cordova Ashley | Chief Financial Officer | 688 0.0006% | $20.14 | $13,857 | -7.92% | |
| 2024-06-04 | Sale | VERNON W ANTHONY | director | 964 0.0009% | $23.89 | $23,033 | -16.89% |
Total: 483
*Gray background shows transactions not older than one year
Insider Historical Profitability
29.19%
| Perlhagen Gert L. | director | 6125000 5.5725% | $119.38M | 1 | 1 | +171.79% |
| Shah Pritesh | Chief Growth Officer | 124511 0.1133% | $2.43M | 1 | 50 | +85.52% |
| MYLOD ROBERT J JR | director | 20000 0.0182% | $389,800.00 | 1 | 0 | <0.0001% |
| Danziger Asaf | Chief Executive Officer | 13583 0.0124% | $264,732.67 | 2 | 55 | <0.0001% |
NVCR Institutional Investors: Active Positions
| Increased Positions | 120 | +43.48% | 10M | +10.53% |
| Decreased Positions | 114 | -41.3% | 11M | -11.77% |
| New Positions | 55 | New | 5M | New |
| Sold Out Positions | 35 | Sold Out | 2M | Sold Out |
| Total Postitions | 282 | +2.17% | 93M | -1.24% |
NVCR Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $309,509.00 | 14.76% | 16.23M | -1,869 | -0.01% | 2024-12-31 |
| Blackrock, Inc. | $248,415.00 | 11.84% | 13.03M | +247,308 | +1.94% | 2024-12-31 |
| Vanguard Group Inc | $224,952.00 | 10.72% | 11.8M | -48,499 | -0.41% | 2024-12-31 |
| Capital International Investors | $169,225.00 | 8.07% | 8.87M | +951,141 | +12.01% | 2024-12-31 |
| Capital World Investors | $91,832.00 | 4.38% | 4.82M | +507,311 | +11.78% | 2024-12-31 |
| Soleus Capital Management, L.P. | $52,246.00 | 2.49% | 2.74M | +3M | New | 2024-12-31 |
| State Street Corp | $50,372.00 | 2.4% | 2.64M | -88,543 | -3.24% | 2024-12-31 |
| Geode Capital Management, Llc | $45,771.00 | 2.18% | 2.4M | -5,075 | -0.21% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $32,237.00 | 1.54% | 1.69M | -1M | -39.76% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $32,110.00 | 1.53% | 1.68M | -638,378 | -27.49% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.